MMAE

MMAE

MMAE is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. Monomethyl auristatin E or MMAE is 100-1000 times more potent than doxorubicin. It is a very potent antimitotic agent that inhibits cell division by blocking the polymerization of tubulin. Please contact us for GMP-grade inquiries.

Molecular structure of the compound BP-22278
    • Unit
    • Price
    • Qty
    • 100 MG
    • $280.00
    • 250 MG
    • $490.00
    • 500 MG
    • $680.00
    • 1 G
    • $995.00

Usually ships within 24 hours.

Would you like to inquire about custom quantity?
Inquire

Product Citations

  1. Itaborahy, M. F., Feng, I. Z., Vieira-Machado, U. F., da Silveira, I. B., Valverde, T. M., Costa, G. M., ... & Leite, M. F. (2025). Chemotherapy-induced neuropathy in monomethyl Auristatin E treatment: prevention by lithium: Cellular and Molecular Biology. British Journal of Cancer, 1-11.
    https://www.nature.com/articles/s41416-025-03020-6
  2. Li, W. F., Chiang, M. F., Weng, H. C., Yang, J. J., Wu, H. S., Wu, S. Y., ... & Lai, M. T. (2025). OBI-992, a Novel TROP2-Targeted Antibody–Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models. Molecular Cancer Therapeutics, 24(2), 163-175.
    https://doi.org/10.1158/1535-7163.MCT-24-0588
  3. Samantha RB, Courtney PJ, Siteng F, et al. Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering. Molecular Pharmaceuticals. 2019; 16(6): pp. 2795-2805.
    https://pubs.acs.org/doi/full/10.1021/acs.molpharmaceut.9b00323